October 4, 2011

Make a Difference for Burkitt Lymphoma – Join the BL Genome Sequencing Project (BLGSP)

Burkitt Lymphoma (BL) is an aggressive (fast growing) form of B-cell non-Hodgkin lymphoma that occurs most frequently in children and young adults. The three main types of BL are sporadic (occurs worldwide); endemic (occurs in Africa); and immunodeficiency related (most often seen in AIDS patients).

In an effort to develop a Genomic Databank for BL, the Foundation for Burkitt Lymphoma Research has teamed with the National Cancer Institute (NCI) to compile genetic changes present in BL tumors, analyze the data to identify diagnostic, prognostic or therapeutic markers or targets, and publish the results with the ultimate goal of improving the detection and treatment of the cancer.

The study is seeking adult and pediatric patients with sporadic BL, as well as people with endemic and HIV-positive sporadic BL, with the objective of generating a complete set of genes which contribute to the development of BL cells. It is anticipated that the project timeline will be three to four years; approximately two years to identify and collect appropriate tissue and data from approximately 120 patients, about six months to complete the sequencing, and another 6 to 18 months to analyze and publish the data.

Patients and researchers are encouraged to participate. For detailed tissue requirements and further information on the BLGSP, please contact the Office of Cancer Genomics Team Representative:

Robin S. Broughton, Ph.D.
Office of Cancer Genomics
National Cancer Institute
31 Center Drive, Suite 10A07
Bethesda, MD 20892
Phone: 301-451-3860
Fax: 301-480-4368